Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/5/2025 | $75.00 | Buy | H.C. Wainwright |
| 2/4/2025 | $49.00 | Outperform | Wolfe Research |
| 1/28/2025 | $58.00 | Buy | Goldman |
| 11/21/2024 | $70.00 | Overweight | Wells Fargo |
| 10/16/2024 | Sector Outperform | Scotiabank | |
| 1/25/2024 | $26.00 | Outperform | Oppenheimer |
| 1/8/2024 | Overweight | Cantor Fitzgerald | |
| 12/18/2023 | $29.00 | Outperform | Raymond James |
BRISBANE, Calif. , July 10, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on July 6, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 133,500 shares of Class A common stock and restricted stock units (RSUs) for 73,695 shares of Class A common stock to fifteen (15) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on July 6, 2025 has an exercise price per share equal to $24.00, Vera's closing trading price on July 3, 2
BRISBANE, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA) today announced that on June 3, 2025, the Compensation Committee granted inducement awards consisting of non-qualified stock options to purchase 124,000 shares of Class A common stock and restricted stock units (RSUs) for 65,925 shares of Class A common stock to seventeen (17) new employees under the Inducement Plan. The Compensation Committee approved the awards as an inducement material to the new employees' employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option granted on June 3, 2025 has an exercise price per share equal to $30.91, Vera's closing trading price on June 3,
BRISBANE, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company's management team will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference, which is taking place in Miami Beach, FL from June 9 – 11, 2025. The management team will also participate in one-on-one investor meetings. Fireside Chat Details:Date: Wednesday, June 11, 2025 Time: 3:15pm EDTWebcast: https://cc.webcasts.com/gold006/060925a_js/?entity=165_UH4O74B A replay of
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
SCHEDULE 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
8-K - Vera Therapeutics, Inc. (0001831828) (Filer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
4 - Vera Therapeutics, Inc. (0001831828) (Issuer)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G/A - Vera Therapeutics, Inc. (0001831828) (Subject)
SC 13G - Vera Therapeutics, Inc. (0001831828) (Subject)
H.C. Wainwright resumed coverage of Vera Therapeutics with a rating of Buy and set a new price target of $75.00
Wolfe Research initiated coverage of Vera Therapeutics with a rating of Outperform and set a new price target of $49.00
Goldman initiated coverage of Vera Therapeutics with a rating of Buy and set a new price target of $58.00
Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001)Other prespecified endpoints achieved similar or better results compared to the ORIGIN Phase 2b clinical trial — per FDA guidance, Vera is not sharing eGFR results at this time while the ORIGIN 3 placebo-controlled trial continuesThe safety profile of atacicept was favorable, and comparable to placebo Vera plans to meet with FDA in the coming weeks to discuss these results and the regulatory pathway; Vera currently plans to submit a Biologics License Application
BRISBANE, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced an exclusive license agreement with Stanford University for a novel, next generation fusion protein targeting BAFF and APRIL, known as VT-109, with wide therapeutic potential across the spectrum of B cell mediated diseases. "This novel approach is part of Vera's broad lifecycle management strategy to expand and extend our leadership position within B cell modulation, which we believe has the potential to transform how we tre
New data at week 36 shows atacicept 150 mg resulted in a delta of 43% versus placebo in mean proteinuria reduction in per-protocol analysis and demonstrated statistically significant stabilization of eGFR versus placebo in this high-risk population Atacicept was well tolerated with safety profile similar to placebo Positive results support atacicept 150 mg as a potential disease-modifying treatment for patients with IgA nephropathy; Phase 3 (ORIGIN 3) clinical trial initiated in June 2023 Conference call and webcast to take place on June 20th, 2023, at 8:00 a.m. ET to further discuss results BRISBANE, Calif., June 17, 2023 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a la
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jason S. Carter as Chief Legal Officer, effective immediately. "We are excited to have Jason join our growing team. With our pivotal ORIGIN 3 trial of atacicept in IgAN on track to announce topline results in the second quarter of 2025 and planned BLA submission to the FDA anticipated later in the year, pending data, we are actively building out our team with experienced professionals who will help us succ
BRISBANE, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of David L. Johnson as Chief Operating Officer, effective immediately. "We are excited to have David join our executive team at this important time for our clinical program of atacicept for the treatment of IgAN. We expect long-term 96-week data from the Phase 2b ORIGIN trial later this year and primary endpoint results from our pivotal Phase 3 clinical trial in the first half of 2025, and we look forward to
BRISBANE, Calif., June 11, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (NASDAQ:VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Christy J. Oliger to its board of directors, effective June 7, 2024. Ms. Oliger brings over 30 years of experience in the biopharmaceutical industry, including being recognized for building highly effective teams and leading significant commercial product launches. "We are delighted to welcome Christy to our Board during this important period in Vera's history. Her extensive experience and counsel will be